Fairooz Kabbinavar, CMO

Fairooz Kabbinavar, CMO

atCardiff Oncology· In proxies 2023–2024

Pay in FY2024+1% from the year before · Cardiff Oncology stock +193.2% the same year

Fairooz Kabbinavar, CMO was paid $1.3M in FY2024 (Dec), up 1%. Cardiff Oncology stock rose 193.2% that year.

Pay$100 in the stock at the end of FY22 → $310
Pay is from the Summary Compensation Table of each Cardiff Oncology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Cardiff OncologyPublic company · 3 yr
    • 2023 – Present · 3 yrStock in role -29%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?